Join to View Full Profile
9430 Key West AveSte 113Rockville, MD 20850
Dr. Zheng is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
NYU Grossman School of MedicineResidency, Pathology-Anatomic and Clinical, 1994 - 1998
Peking Union Medical CollegeClass of 1987
Certifications & Licensure
MD State Medical License 2014 - 2027
DC State Medical License 2015 - 2022
MI State Medical License 2006 - 2022
VA State Medical License 2014 - 2020
OH State Medical License 1998 - 2007
NY State Medical License 1997 - 1999
American Board of Pathology Clinical Pathology
Clinical Trials
- Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC Start of enrollment: 2020 Sep 16
Publications & Presentations
PubMed
- Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial.Byoung Chul Cho, Rama Balaraman, Hua-Jun Chen, Xinmin Yu, Adewale Fawole
Nature Medicine. 2026-03-27 - Specific depletion of TIGITCD226clonally expanded intratumoral Tregs defines safe and effective TIGIT targeting.Haoyue Zhou, Jinmei Li, Song Mei, Meiyu Zhang, Haochen Zhao
Journal for Immunotherapy of Cancer. 2026-02-24 - Drug Development.Peng Wang, Timothy Esworthy, Ido Weiss, Pan Zheng, Yang Liu
Alzheimer's & Dementia. 2025-12-01
Journal Articles
- CD24 and Fc Fusion Protein Protects SIVmac239-Infected Chinese Rhesus Macaque Against Progression to AIDSPan Zheng, MD, ScienceDirect
Press Mentions
BioNTech and OncoC4 Announce Promising Phase 3 Trial Results for Gotistobart (BNT316/ONC-392) in Squamous Non-Small Cell Lung CancerDecember 6th, 2025- China's NMPA Grants Breakthrough Therapy Designation for Anti-CTLA-4 Antibody Candidate Gotistobart (BNT316/ONC-392)October 27th, 2025
- OncoC4 Announces First Patient Dosed in PRESERVE-004, a Phase 2 Clinical Trial of ONC-392 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Platinum-Resistant Ovarian CancerDecember 30th, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
